July 23rd 2024
MK-1654 (clesrovimab) met its primary efficacy endpoint of incidence of patients with RSV-associated medically attended lower respiratory infections (MALRI) through Day 150.
June 28th 2024
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Integrating Guideline-Driven Protocols Into Evidence-Based Practice to Improve Outcomes in Patients With Pulmo...
1.0 Credit / Respiratory
View More
GASp, Where’s the Amoxicillin? Group A Streptococcus Infections and What Pharmacists Need to Know
1.0 Credit / Pulmonology/Respiratory
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Exploring the GOLD Report Updates and the Value of Patient-Centered Strategies for the Treatment of Chronic Ob...
1.0 Credit / Pulmonology/Respiratory
View More
Exploring the GOLD Report Updates and the Value of Patient-Centered Strategies for the Treatment of Chronic Ob...
1.0 Credit / Pulmonology/Respiratory
View More
FDA, DOJ Launch Multi-Agency Task Force to Address Illegal E-Cigarettes
June 11th 2024The new task force highlights a stronger government focus on curbing the risks of e-cigarettes for young people, especially after sustained calls for stricter action on the public health issue by lawmakers and the public.
Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation
April 24th 2024By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.